Navigation Links
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Date:4/23/2008

tion, MT110 may be suited to treat established tumors as well as disseminated cancer cells, which frequently give rise to metastases."

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting EpCAM (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with lung and gastrointestinal cancers. Two additional BiTE antibodies, targeting CD33 and MCSP, are in preclinical development.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and auto
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
6. Micromet Announces Changes in Management Team
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Following a ... Committee that moved H.R. 284, the Medicare DMEPOS ... American Association for Homecare (AAHomecare) released a statement ... action to pass the legislation. "Today,s ... the House Ways and Means Committee is a ...
(Date:2/27/2015)... -- Securities lawyers at Dunnam & Dunnam ... SLXP ) in connection with a buyout ... encouraged to contact attorney Hamilton Lindley by clicking ... the shareholder value of the transaction. Under terms of ... per share in cash. At least one analyst has ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ - ESSA ... Bloom Burton & Co. Ltd. ("Bloom Burton") today announced ... "Lock-Up") 2,353,130 common shares of the Company ("Common Shares") ... the Lock-Up. Of the Common Shares released from the ... release from the Lock-Up while the remainder will be ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4
... Sleep, the West Coast,s largest and fastest growing independent ... sleep clinic in Oakland, California.  Located one block from ... open for business. Services include sleep physician consultations, diagnostic ... other therapies for patients diagnosed with Obstructive Sleep Apnea ...
... Nov. 14, 2011 NeuroCog Trials, Inc. and Advance ... recordings of neurocognitive testing in a large international clinical ... errors in test administration and scoring.  This video recording ... accurate, unbiased assessment of neuropsychological effects of new drugs. ...
Cached Medicine Technology:Bay Sleep Clinic Continues Growth in California and Beyond 2NeuroCog Trials Captures Video Recordings of Neurocognitive Testing in a Multinational Clinical Trial 2NeuroCog Trials Captures Video Recordings of Neurocognitive Testing in a Multinational Clinical Trial 3
(Date:2/28/2015)... The World Scout League Commission (WSLC), an ... EMTs and firefighters, recently announced its decision to host ... raise charitable donations for age-related research. The five-kilometer race, ... held on March 29, 2015; registration will start at ... p.m. , To participate in the race, runners ...
(Date:2/28/2015)... 1Heart Caregiver Services CEO Belina ... at Houston Texas Franchise Expo South and IFA ... executive delegates headed by Vice-President of Operations Kevin ... Randolph Clarito. , Franchise Expo South, sponsored by ... 4-7 and featured Franchise brands of every industry ...
(Date:2/27/2015)... Wireless Analytics, an award-winning ... of the founders of the wireless expense ... within their CLEAN Platform™ (Communications Lifecycle Expense Analytics) ... newly developed Bell Mobility Data Loader enables unprecedented ... carrier’s business customers. , Wireless Analytics cites customer ...
(Date:2/27/2015)... A new study published in the Journal of ... on a regular basis and prostate cancer. While cycling is ... more hours per week a man spends cycling, the more ... increased importance on prostate cancer screening methods. , “This study ... at patents’ risk factors for developing prostate cancer,” says Kia ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 ... “cutters”, are often misunderstood, misdiagnosed and therefore ... to healthy lives. Jacksonville-based addiction treatment ... of its highly acclaimed Lakeview Professional Lecture ... interested in understanding this complicated condition. ...
Breaking Medicine News(10 mins):Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2
... It's no surprise that constant stress can make people sick, ... ,A study focused on 119 men and women who were ... caregivers was compared with that of 106 people of similar ... care giving. Blood tests showed that a chemical called Interleukin-6 ...
... million children worldwide die every year, most of them in ... treatments. While the childhood mortality rate in these nations has ... peaked in 1980. About half of the deaths in children ... Pakistan, Democratic Republic of Congo, and Ethiopia) and 90 percent ...
... who are bitten by animals poses little problem for doctors, ... human? ,That’s the question researchers set out to answer in ... and Neck Surgery. Their review of 10 years worth of ... believe can form a standard protocol to follow when man ...
... for preventing disease. In the future, skin ,cancer detection may ... Hattaway is a nine-year ,survivor of melanoma. He’s lucky doctors ... never found a primary, which is what you call the ... the skin. It had already gotten into my lymph system,” ...
... to prevent or delay the onset of prostate cancer, ... cancers. ,More than 18,000 men were randomized , age ... At baseline, digital rectal examination results were normal in ... more than 3.0 ng/mL. Among the 4368 men in ...
... delay the onset of prostate cancer, however, finasteride may ... 18,000 men were randomized , age 55 or older ... rectal examination results were normal in all subjects, and ... ng/mL. Among the 4368 men in the finasteride group ...
Cached Medicine News:
Inquire...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTP/1Q-PAL chairs are recommended for ... clean room, static control, health care ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With polished ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
Medicine Products: